IBA Molecular has acquired Mallinckrodt’s Nuclear Medicine business

discover more

Creates a world-class radiopharmaceuticals group

discover more

Serving life-saving diagnostic solutions to over 14 million patients annually

discover more

Supplying 6,000 private and public hospitals across the globe

discover more

Committed to best-in-class service to our customers

discover more

About our merger

Our merger brings together two leading nuclear imaging businesses with complementary strengths, manufacturing capabilities, commercial footprints and operational networks. Our enlarged business will employ over 1,500 people globally, supplying more than 6,000 public and private hospitals around the world. Annually, our combined business will provide potentially life-saving diagnostic solutions to 14 million patients globally.

Nuclear imaging at our core
Nuclear imaging will continue to be at the core of our enlarged business and we plan to invest further in organic and in-organic growth opportunities. We are very excited about our future potential and our ability to deliver substantial benefits to our customers and their patients.

About IBA Molecular

IBA Molecular is a highly diversified global supplier of molecular imaging and other proven technologies in nuclear medicine, mainly SPECT and PET products. Our company operates across 18 sites globally, servicing a growing client base of private hospitals and health/imaging clinics in over 70 countries. We produce radioactive tracers used in molecular imaging and therapy to diagnose and monitor a range of common diseases including cancer, heart, brain and bone. IBA Molecular was created in 2012 following the buy-out of the radiopharmaceutical division of Ion Beam Applications (“IBA SA”), a European leader in advanced cancer radiation therapy.  In 2016, IBA Molecular was acquired by CapVest.

About Nuclear Medicine Business Acquired from Mallinckrodt

Mallinckrodt’s Nuclear Medicine business is a global producer of the medical isotope molybdenum-99, and its derivative, Technetium-99m, which is used in nuclear medicine procedures worldwide. Our business has manufacturing operations in the US and the Netherlands, close to critical transport links, and our products are approved for use in many countries. Over two-thirds of our revenues originate in the US.

Our Advanced Products

Nuclear medicine is essential in monitoring all major diseases. Ensuring a steady, uninterrupted supply of these life saving solutions is a high priority for us as is our absolute commitment to safety at every stage between production and patients. Our products include generators, cold kits, hot products and auxiliary products used in the diagnosis and treatment of a wide range of diseases affecting the thyroid, lungs, liver, bones, brain, heart, glands, kidneys and joints.

Our Unrivalled Production Capabilities

Our business comprises 21 manufacturing centres (including 3 SPECT sites, 1 molybdenum manufacturing facility and 17 PET sites) along with commercial operations across 60 countries that enables us to deliver significant economies of scale. Our main production facilities are located in Saclay, France, Petten in the Netherlands and Maryland Heights, Missouri in the US.

A New Name to Reflect a New Vision and Ambition

To reflect the future ambition of our expanded business, a new name and brand is currently being developed which is due to be launched in the coming months. In the meantime, we will continue to engage with customers and suppliers as IBA Molecular and Mallinckrodt Nuclear Imaging and it will be business as usual for customers and suppliers.

Subscribe to our newsletter

Enter your details to get frequent updates on the company including its participation in upcoming conferences.